Enfuvirtide

恩夫韦肽

Report date: 2022/01/14 13:23:58
NMEFirst In Class

Base Information

Drug NameEnfuvirtide
Drug Alias Nameenfuvirtide恩夫韦地enfuvirtidaenfuvirtidumFuzeon +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHIV fusion inhibitorsTransmembrane glycoprotein gp41 inhibitors
TargetsTransmembrane glycoprotein gp41
Therapy Area/IndicationsAcquired Immunodeficiency SyndromeHIV Infections
Global Approved IndicationsHIV Infections
Approved Indications in ChinaHIV Infections
Original Approved Country/TerritoryUnited States
Original Approved Date2003/03/13
Country/TerritoryBelgiumCanadaUnited States +[15] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesF. Hoffmann-La Roche LtdRoche Registration Gmbh
Inactive CompaniesTrimerisNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsHIV Infections
Inactive IndicationsAcquired Immunodeficiency Syndrome

Other Information

ATC CodeJ05AX07
Related LinksWikipediaDrugBankKEGG